Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells - Wikidata - wikimedia - TriplyDB

Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

http://www.wikidata.org/entity/Q34221822

about

Role of Biomarkers in the Development of PARP Inhibitors PARP inhibitors in the management of breast cancer: current data and future prospects Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor.Histone deacetylase inhibitors prevent pulmonary endothelial hyperpermeability and acute lung injury by regulating heat shock protein 90 function.mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.The histone deacetylase inhibitor SAHA induces HSP60 nitration and its extracellular release by exosomal vesicles in human lung-derived carcinoma cells.Expression of cancerous inhibitor of protein phosphatase 2A in human triple negative breast cancer correlates with tumor survival, invasion and autophagy.Reverse the Resistance to PARP Inhibitors.Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents.PARP inhibitors as antitumor agents: a patent update (2013-2015).Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.Panobinostat for the treatment of acute myelogenous leukemia.The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC.Biology and Management of Patients With Triple-Negative Breast Cancer.Genetic variation in the DNA repair pathway as a potential determinant of response to platinum-based chemotherapy in breast cancer.Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma.Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat.Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes.PARP inhibitors: the journey from research hypothesis to clinical approval.Co-targeting driver pathways in prostate cancer: two birds with one stone.MutT homolog 1 counteracts the effect of anti-neoplastic treatments in adult and pediatric glioblastoma cells.PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy

P2860

Q26753159-58567999-4476-463C-A353-42D15198330A Q26798352-17EA994B-9946-4225-8E4B-897913203C58 Q26823419-C9FB1E08-C4B6-4BFF-8008-380BEE07615C Q27853152-D11004E2-A37D-45BE-AE11-D38DDAFE6DA3 Q28552235-DB44FCBD-CA0C-4516-A3B6-08458EEA5E35 Q29147555-25C8E103-5C16-4586-97C9-F04C40CE7A00 Q33441772-F0F195BA-00D9-4180-A39A-837A17A2CA26 Q35588352-3531F477-57CB-4D1C-ABF5-0345B1619BAA Q35741555-5A42BB66-7196-4847-84B8-6EA6B68063CB Q35741591-671E126B-8329-4A79-BCBC-D94ED2EE5A94 Q35742395-DF1BDB71-57F1-4144-89B5-DD8A630637FA Q36382137-BCDF361B-88B8-407F-9CF2-676502BD3299 Q36874139-627DE21E-CD8C-4710-9D86-5640B105F799 Q36876973-1B918715-C700-4D6E-B265-B687B8AF4B14 Q37301688-9511F29D-12A4-4038-AF57-18C03CACE27E Q37581930-9808A4E3-2645-4355-BB65-4273111192EB Q37675896-411D840D-4CB4-44B6-A81F-665FC0C28129 Q37702227-0B8709DD-6C56-4874-B92F-8AF8C4CE4ED3 Q38647802-C0972258-DD1A-4321-8EC6-DC8C32EBEC22 Q38752928-D883367E-B615-42C8-8C8B-20BC4B6843EE Q38795712-BAF6C2AC-33A0-45C3-B00A-082999043764 Q38825945-928F257C-CA47-44B3-95DC-75385D776415 Q38835113-FFD7F461-BDE6-402D-BBAB-FD26A4875F27 Q38878715-D43335A1-3E26-40CC-80CA-5276E2E3A8AB Q38893074-AD150522-A4A7-483C-992B-95BEDF8B01AA Q39428059-1DD7072E-4432-4FA5-A658-E8F238F79C70 Q40078610-0799A36F-BA97-44EC-B103-231728BFAEB5 Q41347312-8C9FE9AF-2BE2-4D47-94B6-5D81ABAB5DD0 Q48023755-F43E2485-EB7C-4DEC-8197-3BB6CEB50012 Q52646057-8D705A30-4C2D-4ED3-8C06-7698A7BE7EA5 Q53682668-CD8A41B7-3FC4-4F99-9101-78EAA2310C35 Q54965982-085BDF83-5F1E-4062-A9FB-6756C00FE34D Q55398218-B3753140-BF73-4018-92DF-7DEEEC9C30FB Q57175832-7441CB42-DE33-4C57-8793-E9206DAB4E9B Q58719363-7271C1CA-AF52-42DF-A6BB-B4931E5B6B8C

P2860

Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

http://www.wikidata.org/entity/Q34221822

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Histone deacetylase inhibitor ...... e negative breast cancer cells

@ast

Histone deacetylase inhibitor ...... e negative breast cancer cells

@en

Histone deacetylase inhibitor ...... e negative breast cancer cells

@nl

type

label

Histone deacetylase inhibitor ...... e negative breast cancer cells

@ast

Histone deacetylase inhibitor ...... e negative breast cancer cells

@en

Histone deacetylase inhibitor ...... e negative breast cancer cells

@nl

prefLabel

Histone deacetylase inhibitor ...... e negative breast cancer cells

@ast

Histone deacetylase inhibitor ...... e negative breast cancer cells

@en

Histone deacetylase inhibitor ...... e negative breast cancer cells

@nl

P1433

Q34221822-27AD9F0B-11D1-469D-B38F-801FF5E74DFC

P1476

Q34221822-1A6A2805-FAC3-49DE-BA6B-0785F9EDF085

P2093

Q34221822-33E19526-CD5E-4ABB-8CEE-2AC19A485CAC

Q34221822-37D036B4-99FE-423B-BBB8-5FED6A12AA65

Q34221822-5E28EA0D-95ED-4992-93E8-A444DA07BE06

Q34221822-64D09DF3-C5E0-4830-85A9-57FED38AB785

Q34221822-79D2E8CD-899D-43DB-92BD-B2635E8687BA

Q34221822-93E367A6-27F5-42DB-957F-3584DEC8A3D3

Q34221822-95732DB1-23FD-4C8C-BE90-706AEE5D6FFF

Q34221822-BF31FD98-8A6F-44A5-9783-9CABA9BAA091

Q34221822-C7CBADA8-A37B-45E1-9420-5BEAB2E9E016

Q34221822-E72CE014-35CA-438A-A56B-72EC845FB1C3

P2860

Q34221822-09861781-BD2B-4216-B3B0-18C4F49CF14E

Q34221822-0C5F0341-A2EE-4FB2-BC9E-8FE7D5256DB1

Q34221822-1195AF98-AEE8-46E6-9704-DAAF552FDA24

Q34221822-1271718E-E63A-491A-8291-908F853C3FC1

Q34221822-16BEFACF-C877-4641-BDC5-87B93F46DE5E

Q34221822-1E4ABF53-D82A-4CC9-8D3C-DDD1839F402E

Q34221822-2016144A-FA81-468B-A077-177509EE822E

Q34221822-2417115A-BA95-4E2E-A4B7-5B8A56058A01

Q34221822-25832498-05C5-4465-94AA-C9385AFF505C

Q34221822-2B9C7082-2C6E-4CCA-BDEF-AB714C590DF0

P304

Q34221822-C5E5BD64-2BB4-478A-9C57-040E504D653D

P31

Q34221822-B660F5AD-5CE5-4F88-A3DB-51F77238A97C

P356

Q34221822-84E33C38-B0B6-451F-B71B-DF643930F24D

P407

Q34221822-2D2AF65B-D207-4990-8BC0-A478A18FC8EE

P433

Q34221822-ED5B7A8F-D217-42C2-B391-AA5E9982A9EA

P478

Q34221822-3B701A60-3740-42EC-8C90-C50D046687AC

P50

Q34221822-8216D713-D302-4CC0-96E4-BF38303049F1

P577

Q34221822-40E21D76-14FF-4544-BB83-0B688D8EEF4D

P5875

Q34221822-B9880EC5-5802-459C-B213-F211867F2E3E

P698

Q34221822-DB10F0A1-CCA5-4C8D-B6F9-B8C7E5718112

P932

Q34221822-C8BE5DC7-1B42-4CE9-AF42-447BFCBD1BF8

P356

ONCOTARGET.2154

P1433

P1476

Histone deacetylase inhibitor ...... e negative breast cancer cells

@en

P2093

Ari M Melnick

http://www.w3.org/2001/XMLSchema#string

Bhavin Shah

http://www.w3.org/2001/XMLSchema#string

Dong Soon Choi

http://www.w3.org/2001/XMLSchema#string

Jenny C Chang

http://www.w3.org/2001/XMLSchema#string

Kapil N Bhalla

http://www.w3.org/2001/XMLSchema#string

Kyungsoo Ha

http://www.w3.org/2001/XMLSchema#string

Santhana G T Devaraj

http://www.w3.org/2001/XMLSchema#string

Scott Hiebert

http://www.w3.org/2001/XMLSchema#string

Srividya Bhaskara

http://www.w3.org/2001/XMLSchema#string

Sunil Sharma

http://www.w3.org/2001/XMLSchema#string

P2860

Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.

The DNA Damage Response: Making It Safe to Play with Knives

Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion

The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer

Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate

53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

Hallmarks of 'BRCAness' in sporadic cancers

P304

5637-5650

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.2154

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Leandro Cerchietti

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263972819

http://www.w3.org/2001/XMLSchema#string

P698

25026298

http://www.w3.org/2001/XMLSchema#string

P932

4170637

http://www.w3.org/2001/XMLSchema#string